Riboflavin protects mice against liposaccharide-induced shock through expression of heat shock protein 25

被引:21
作者
Shih, Chun-Kuang [1 ]
Chen, Chiao-Ming [2 ]
Chen, C. -Y. Oliver [3 ]
Liu, Jen-Fang [1 ]
Lin, Hui-Wen [4 ]
Chou, Hung-Tsung [5 ]
Li, Sing-Chung [1 ]
机构
[1] Taipei Med Univ, Sch Nutr & Hlth Sci, Taipei 110, Taiwan
[2] Shih Chien Univ, Dept Food Sci Nutr & Nutraceut Biotechnol, Taipei 110, Taiwan
[3] Tufts Univ, Antioxidants Res Lab, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA
[4] Taipei Med Univ, Biostat Res & Consulting Ctr, Taipei 110, Taiwan
[5] Taipei Med Univ, Div Emergency Med, Wan Fang Hosp, Taipei 110, Taiwan
关键词
Vitamin B2; Lipopolysaccharide; Sepsis; Heat shock protein 25; Heat shock factor 1; HIGHLY PURIFIED VITAMIN-B-2; IMPROVES SURVIVAL; ENDOTOXIN-SHOCK; LUNG INJURY; SEPSIS; CYTOKINE; LIPOPOLYSACCHARIDE; PLASMA; DEATH;
D O I
10.1016/j.fct.2010.04.033
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
Riboflavin (vitamin B2) is a water-soluble vitamin essential for normal cellular functions, growth and development. This study aimed to investigate the effects of vitamin B2 on the survival rate, and expressions of tissue heat shock protein 25 (HSP25) and heat shock factor 1 (HSF1) in mice undergoing lipopolysaccharide (LPS) induced shock. Mice were assigned to four groups, saline vehicle, LPS, LPS plus low dose of vitamin B2 (LB2) and LPS plus high dose of vitamin B2 (HB2). Vitamin B2 (1 and 10 mg/kg BW) was administered intraperitoneally at 2 and 0 h before the i.p. administration of LPS. At the end of the experiment, the survival rate monitored was 10, 20, 60, and 100% for LPS, LB2, HB2, and saline mice, respectively. HSP25 expressions in the heart and lung were significantly enhanced in a time-dependent manner in the HB2 mice as compared to the saline mice (p<0.05), but not altered in the LB2 mice. In the HB2 mice, plasma riboflavin concentrations reached 300 nM at 6 h post LPS and returned to the 0 h level at 72 h. The results showed that high dose of riboflavin could decrease LPS-induced mortality through an increased expression of HSP25. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1913 / 1918
页数:6
相关论文
共 35 条
[21]   Impaired inducibility of heat shock protein 70 in peripheral blood lymphocytes of patients with severe sepsis [J].
Schroeder, S ;
Lindemann, C ;
Hoeft, A ;
Putensen, C ;
Decker, D ;
von Ruecker, AA ;
Stüber, F .
CRITICAL CARE MEDICINE, 1999, 27 (06) :1080-1084
[22]   Glutamine attenuates lung injury and improves survival after sepsis: Role of enhanced heat shock protein expression [J].
Singleton, KD ;
Serkova, N ;
Beckey, VE ;
Wischmeyer, PE .
CRITICAL CARE MEDICINE, 2005, 33 (06) :1206-1213
[23]   Glutamine prevents activation of NF-κB and stress kinase pathways, attenuates inflammatory cytokine release, and prevents acute respiratory distress syndrome (ARDS) following sepsis [J].
Singleton, KD ;
Beckey, VE ;
Wischmeyer, PE .
SHOCK, 2005, 24 (06) :583-589
[24]   Potentiation by amino acid of the therapeutic effect of highly purified vitamin B2 in mice with lipopolysaccharide-induced shock [J].
Toyosawa, T ;
Suzuki, M ;
Kodama, K ;
Araki, S .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 493 (1-3) :177-182
[25]   Effects of intravenous infusion of highly purified vitamin B2 on lipopolysaccharide-induced shock and bacterial infection in mice [J].
Toyosawa, T ;
Suzuki, M ;
Kodama, K ;
Araki, S .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 492 (2-3) :273-280
[26]   Highly purified vitamin B2 presents a promising therapeutic strategy for sepsis and septic shock [J].
Toyosawa, T ;
Suzuki, M ;
Kodama, K ;
Araki, S .
INFECTION AND IMMUNITY, 2004, 72 (03) :1820-1823
[27]   Cytokine function of heat shock proteins [J].
Tsan, MF ;
Gao, BC .
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2004, 286 (04) :C739-C744
[28]   Antiinflammatory cytokine responses during clinical sepsis and experimental endotoxemia: Sequential measurements of plasma soluble interleukin (IL)-1 receptor type II, IL-10, and IL-13 [J].
vanderPoll, T ;
Malefyt, RD ;
Coyle, SM ;
Lowry, SF .
JOURNAL OF INFECTIOUS DISEASES, 1997, 175 (01) :118-122
[29]  
VILLAR J, 1994, CRIT CARE MED, V22, P914
[30]  
Vincent JL, 2003, INTENS CARE MED, V29, pS74